LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment

2019 ◽  
Vol 70 (1) ◽  
pp. e128 ◽  
Author(s):  
PD Dr. Schattenberg Jörn ◽  
Albert Parés ◽  
Kris V. Kowdley ◽  
Michael Heneghan ◽  
Stephen Caldwell ◽  
...  
Keyword(s):  
Ursodeoxycholic Acid ◽  
Acid Treatment ◽  
Primary Biliary Cholangitis ◽  
Peroxisome Proliferator ◽  
Inadequate Response ◽  
Efficacy And Safety ◽  
Receptor Alpha

Clinical Trials in PBC Going Forward

2019 ◽  
Vol 39 (03) ◽  
pp. e1-e6
Author(s):  
Christophe Corpechot
Keyword(s):  
Clinical Trials ◽  
Ursodeoxycholic Acid ◽  
Standard Of Care ◽  
Farnesoid X Receptor ◽  
Primary Biliary Cholangitis ◽  
Peroxisome Proliferator ◽  
Personal View ◽  
Standard Of Care Treatment ◽  
Peroxisome Proliferator Activated Receptors ◽  
New Treatments

AbstractNew treatments for primary biliary cholangitis (PBC) are progressively emerging, including first and second generations of farnesoid X receptor and peroxisome proliferator-activated receptors agonists. Even though ursodeoxycholic acid monotherapy remains the standard of care treatment for PBC, these additional therapeutic options, already or soon to be available, lead us to revise our priorities and strategies with respect to future clinical trials. The present article is a personal view of where we currently stand in this field and where and how we should be going to achieve new progress.

scholarly journals Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis

2021 ◽  
Vol 000 (000) ◽  
pp. 000-000
Author(s):  
Yanyun Shu ◽  
Yuhu Song ◽  
Tao Bai ◽  
Xiaoli Pan ◽  
Haitao Shang ◽  
...  
Keyword(s):  
Ursodeoxycholic Acid ◽  
Predictive Model ◽  
Treatment Response ◽  
Acid Treatment ◽  
Primary Biliary Cholangitis

Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis

2020 ◽  
Vol 115 (2) ◽  
pp. 262-270 ◽  
Author(s):  
Stuart C. Gordon ◽  
Kuan-Han Hank Wu ◽  
Keith Lindor ◽  
Christopher L. Bowlus ◽  
Carla V. Rodriguez ◽  
...  
Keyword(s):  
Overall Survival ◽  
African Americans ◽  
Ursodeoxycholic Acid ◽  
Acid Treatment ◽  
Primary Biliary Cholangitis

What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?

2017 ◽  
Vol 35 (4) ◽  
pp. 359-366 ◽  
Author(s):  
Lin Lee Wong ◽  
Vinod S. Hegade ◽  
David E.J. Jones
Keyword(s):  
Ursodeoxycholic Acid ◽  
Disease Progression ◽  
Farnesoid X Receptor ◽  
European Medicines Agency ◽  
Primary Biliary Cholangitis ◽  
Inadequate Response ◽  
Primary Therapy ◽  
Chronic Cholestasis ◽  
Increased Risk ◽  
Risk Of Disease

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by chronic cholestasis. Treatment with the accepted primary therapy ursodeoxycholic acid (UDCA) has been shown to be associated with delayed disease progression probably through reduced impact of cholestatic injury on the target biliary epithelial cells. Patients with inadequate response to UDCA (which can be identified through validated biochemical criteria) are at increased risk of disease progression, need for liver transplantation, and death. Obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second-line therapy in PBC and has been recently licensed by the Food and Drug Administration and European Medicines Agency for use in patients showing an inadequate response to UDCA or who are unable to tolerate it. Although evidence for biochemical improvement by OCA is compelling, there is, as yet, no evidence that OCA improves hard clinical outcomes or quality of life. In addition, OCA may not be suitable for PBC patients with pruritus as it can worsen the symptom. Other novel agents currently in clinical development may have better side-effect profile. Fibrates have the potential but currently lack high quality evidence to support their routine clinical use in PBC. Symptom management of PBC is challenging and ASBT inhibitors and rituximab are being evaluated for pruritus and fatigue, respectively.

Sign in / Sign up

Export Citation Format

Share Document